Yengo Raymond Kimbung (Raymond Kimbung)

Years Active: 2020-2022
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Mark F Maurer, Katherine E Lewis, Joseph L Kuijper, Dan Ardourel, Chelsea J Gudgeon, Siddarth Chandrasekaran, Sherri L Mudri, Kayla N Kleist, Chris Navas, Martin F Wolfson, Mark W Rixon, Ryan Swanson, Stacey R Dillon, Steven D Levin, Yengo Raymond Kimbung, Masato Akutsu, Derek T Logan, Björn Walse, Kristine M Swiderek, Stanford L Peng
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity. Nature communications 13 (1) (2022)
Akos Nyerges, Tihomir Tomašič, Martina Durcik, Tamas Revesz, Petra Szili, Gabor Draskovits, Ferenc Bogar, Žiga Skok, Nace Zidar, Janez Ilaš, Anamarija Zega, Danijel Kikelj, Lejla Daruka, Balint Kintses, Balint Vasarhelyi, Imre Foldesi, Diána Kata, Martin Welin, Yengo Raymond Kimbung, Dorota Focht, Lucija Peterlin Mašič, Csaba Pál
Rational design of balanced dual-targeting antibiotics with limited resistance. PLoS biology 18 (10) (2020)

Yengo Raymond Kimbung.css-eqlu8i{font-size:small;padding-left:4px;} (Raymond Kimbung)